S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
NASDAQ:GERN

Geron Stock Forecast, Price & News

$1.79
-0.05 (-2.72 %)
(As of 12/2/2020 04:32 PM ET)
Add
Compare
Today's Range
$1.78
Now: $1.79▼
$1.85
50-Day Range
$1.74
MA: $1.87▼
$2.05
52-Week Range
$0.75
Now: $1.79▼
$2.40
Volume2.50 million shs
Average Volume2.60 million shs
Market Capitalization$555.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Geron logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.41 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
Previous Symbol
CUSIP37416310
CIK886744
Webwww.geron.com
Phone650-473-7700
Employees45

Debt

Debt-to-Equity Ratio0.10
Current Ratio9.60
Quick Ratio9.60

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$460,000.00
Price / Sales1,208.14
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.75 per share
Price / Book2.39

Profitability

EPS (Most Recent Fiscal Year)($0.36)
Net Income$-68,550,000.00
Net Margins-21,631.02%
Return on Equity-43.76%
Return on Assets-37.24%

Miscellaneous

Outstanding Shares310,472,000
Market Cap$555.74 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$1.79
-0.05 (-2.72 %)
(As of 12/2/2020 04:32 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Geron (NASDAQ:GERN) Frequently Asked Questions

How has Geron's stock price been impacted by COVID-19?

Geron's stock was trading at $1.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GERN shares have increased by 75.2% and is now trading at $1.8050.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Geron?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Geron or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Geron?

Wall Street analysts have given Geron a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Geron wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Geron.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. Geron had a negative net margin of 21,631.02% and a negative return on equity of 43.76%.
View Geron's earnings history.

What price target have analysts set for GERN?

6 brokers have issued 12-month target prices for Geron's shares. Their forecasts range from $3.00 to $7.00. On average, they expect Geron's share price to reach $4.00 in the next year. This suggests a possible upside of 121.6% from the stock's current price.
View analysts' price targets for Geron.

Who are some of Geron's key competitors?

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Ionis Pharmaceuticals (IONS).
View all competitors.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

Who are Geron's key executives?

Geron's management team includes the following people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 69, Pay $1.15M)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 51, Pay $687.17k)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 56, Pay $705.69k)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 56, Pay $673.36k)
  • Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 45, Pay $968.2k)
  • Ms. Suzanne Messere, Head of Investor Relations & Corp. Communications
  • Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 70)
  • Ms. Shannon Odam, VP of HR
  • Mr. Anil Kapur, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 50)

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.92%), NEA Management Company LLC (4.34%), State Street Corp (3.75%), Great Point Partners LLC (3.12%), Charles Schwab Investment Management Inc. (0.65%) and Samsara BioCapital LLC (0.49%). Company insiders that own Geron stock include Elizabeth G O'farrell and Melissa Kelly Behrs.
View institutional ownership trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Samsara BioCapital LLC, Morgan Stanley, WINTON GROUP Ltd, Jane Street Group LLC, Virtus ETF Advisers LLC, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Geron.

Which major investors are buying Geron stock?

GERN stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, State Street Corp, BlackRock Inc., SG Americas Securities LLC, California Public Employees Retirement System, Charles Schwab Investment Management Inc., California State Teachers Retirement System, and UBS Asset Management Americas Inc..
View insider buying and selling activity for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.81.

How big of a company is Geron?

Geron has a market capitalization of $560.40 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 45 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.